Disclaimer
We are a pioneer in treating drug-resistant fluid overload, a serious and frequent clinical complication in patients with liver disease and heart failure.
alfapump® and DSR® are Sequana Medical’s proprietary approaches that work with the body to remove this excess fluid. While DSR is still in development, alfapump® is delivering clinical and quality of life benefits for patients and reducing costs for healthcare systems. We are listed on Euronext Brussels, headquartered in Ghent, Belgium and also have offices in Zurich, Switzerland.
We embrace diversity and inclusion. You will have the opportunity to work with outstanding business teams and contribute to the success of the company. We strive to provide all our employees with the means to develop their skills and experiences, at every level.
Sequana Medical is a pioneer in treating fluid overload, a serious and frequent clinical complication in patients with liver disease, heart failure and cancer, when diuretics are no longer effective. alfapump® and DSR® are Sequana Medical’s proprietary approaches that work with the body to remove the excess fluid, delivering major clinical and quality of life benefits for patients and reducing costs for healthcare systems. We are looking for a technically skilled, hands-on individual to join our small and dynamic manufacturing team in Zurich as
Join a great team responsible for manufacturing high-tech medical devices that improve quality of life. As a Production Assembler, you will assemble and test our implantable pump, catheters, and accessories according to defined procedures. The work is primarily carried out in a clean room, often under a microscope.
Does this opportunity sound exciting? Join our dynamic team in the heart of Zurich!
Send your CV and full application (in English or German, PDF format) to careers@sequanamedical.com.
We look forward to hearing from you!
De alfapump® is nog steeds in klinisch onderzoek in de VS en Canada en daarom zijn alle uitspraken met betrekking tot veiligheid en werkzaamheid niet van toepassing in deze gebieden.
De DSR-therapie is nog in ontwikkeling en het moet worden opgemerkt dat alle uitspraken met betrekking tot veiligheid en werkzaamheid voortkomen uit lopend preklinisch en klinisch onderzoek dat nog moet worden voltooid.
Er is geen verband tussen de DSR-therapie en lopende onderzoeken met het alfapump® systeem in Europa, de VS en Canada.
U.S. Centers for Disease Control and Prevention, Health, United States 2016, Chartbook on Long-term trends in Health, Table 20 (website)
GlobalData NASH Epidemiology Forecast to 2026
Runyon et al. (2009)
Europese Vereniging voor Leveronderzoek EASL richtlijnen klinische praktijk voor het beheer van ascites, spontane bacteriële buikvliesontsteking en hepatorenaal syndroom bij cirrose. Journel of Hepatology. 2010 vol. 53. 397-417. p. 402.
Wereldgezondheidsorganisatie Internationaal Agentschap voor Kankeronderzoek 2018 (http://gco.iarc.fr/today/home) (geschat aantal nieuwe borst- en eierstokkankers in 2018 (bruto cijfer))
Ayantunde et al. (2006)
Benjamin et al. (2013)
Costanzo et al. (2007)
Kilgore et al. (2017)
Kilgore et al. (2017); Ambrosy et al. (2014)
Testani JM, Hanberg JS, Cheng S, et al. Rapid and Highly Accurate Prediction of Poor Loop Diuretic Natriuretic Response in Patients With Heart Failure. Circulation Heart failure. 2016;9(1):e002370. doi:10.1161/CIRCHEARTFAILURE.115.002370.
Ginès et al. (2004) (verklarende dat refractaire ascites zich voordoet bij 5 tot 10 procent van de patiënten met ascites)
Estes et al. (2018)
United States
Stay on sequanamedical.com
Europe
Go to alfapump.com